Jefferies Group LLC Ardelyx, Inc. Transaction History

Jefferies Group LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.65 - $1.18 $72,667 - $131,919	-111,796 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.86 - $1.7 $96,144 - $190,053	111,796 New	111,796 $53,000
Q4 2020 Feb 16, 2021	SELL	$5.05 - $7.1 $352,121 - $495,061	-69,727 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$5.25 - $7.08 $166,167 - $224,089	31,651 Added 83.13%	69,727 $366,000
Q2 2020 Nov 02, 2020	BUY	$5.37 - $8.11 $204,468 - $308,796	38,076 New	38,076 $263,000
Q2 2020 Aug 14, 2020	SELL	$5.37 - $8.11 $216,099 - $326,362	-40,242 Closed	0 $0
Q1 2020 Nov 24, 2020	BUY	$4.35 - $8.79 $175,052 - $353,727	40,242 New	40,242 $232,000
Q1 2020 May 15, 2020	SELL	$4.35 - $8.79 $198,181 - $400,463	-45,559 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$4.23 - $8.29 $23,514 - $46,084	5,559 Added 13.9%	45,559 $342,000
Q3 2019 Nov 13, 2019	BUY	$2.15 - $6.28 $86,000 - $251,200	40,000 New	40,000 $188,000
Q3 2018 Nov 14, 2018	SELL	$3.75 - $4.65 $68,625 - $85,095	-18,300 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $67,710 - $106,140	18,300 New	18,300 $68,000

209

144M

1.01M

1.43M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $994M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.